Spinal Muscular Atrophy Carrier Screening in UAE | 1500 AED | DHA-Approved

Executive Summary & Core Metrics

99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM.
Telephonic post-test clinical guidance for result interpretation.
Direct Billing Verification & Insurance Support via WhatsApp +971 54 548 8731.

Test Overview & Methodology

Spinal Muscular Atrophy (SMA) carrier screening detects deletions or mutations in the SMN1 gene to identify individuals at risk of transmitting SMA to their offspring. This test uses MLPA (Multiplex Ligation-dependent Probe Amplification), the gold-standard methodology for precise copy number analysis of SMN1 and SMN2.

Feature	Our Test (MLPA)	Closest Alternative (Standard PCR/qPCR)
Precision	Detects exon-level deletions/duplications of SMN1 & SMN2 copy number – >99.9% sensitivity	May miss subtle copy number variations and gene conversion events
Methodology	MLPA – gold standard for carrier screening	Targeted PCR with melt curve analysis or NGS panels (lower resolution for SMN)
Turnaround	7–10 days	10–14 days

Physician Insight & Safety Protocols

“A positive carrier result is not a diagnosis of disease, but a starting point for genetic counselling. I encourage couples to interpret this test alongside family history and a clinical geneticist’s evaluation. We never recommend making medical decisions based solely on a single screening result.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Pre-Test Consultation

Important Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Inform the phlebotomist about any anticoagulant therapy before sample collection.

Safety Exclusion Criteria & Emergency Red Flags

This test is not intended for acute symptom diagnosis; do not delay emergency care.
Do not undergo this test if you have a known bleeding disorder without physician clearance.
Seek immediate medical attention if you experience excessive, uncontrolled bleeding after the blood draw.
For minors, Federal Decree-Law No. 4 of 2016 on Medical Liability mandates explicit parental consent and clinical necessity documentation.
Test results are not standalone – always correlate with clinical findings and genetic counselling.

Patient FAQ & Clinical Guidance

1. What is being tested in SMA carrier screening, and why is it important?

Snippet: This test identifies common SMN1 gene deletions that cause spinal muscular atrophy when both parents are carriers.

SMA carrier screening uses MLPA to precisely measure SMN1 copy number, revealing whether you carry a deletion associated with the disease. It is vital for family planning because if both partners are carriers, each pregnancy has a 25% risk of SMA.

2. How should I prepare, and does a doctor’s prescription apply?

Snippet: No fasting or special preparation is needed, but a valid doctor’s prescription is required except for surgery, pregnancy, or travel abroad.

The test requires a simple peripheral blood draw. Per UAE regulations, a prescription is mandatory unless you are undergoing the test for pre‑surgical clearance, pregnancy screening, or travel documentation. A phlebotomist will collect the sample during home visit; just ensure you are well‑hydrated.

3. What does a positive result mean, and what should I do next?

Snippet: A positive result indicates you are a carrier; you should schedule genetic counselling and consider partner testing immediately.

Carriers typically have no symptoms; however, knowing your status empowers informed reproductive choices. We recommend a joint consultation with a clinical geneticist and testing the partner. If both are carriers, prenatal diagnosis or pre‑implantation genetic testing can be discussed. Our telephonic post‑guidance will connect you with specialists.

UAE Regulatory & Data Privacy Adherence

Compliance with UAE Data Protection and Health Information Laws

All personal and genetic data are processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. No data is shared with third parties without explicit written consent.

Clinical & Logistical Metadata

Test Name	Spinal Muscular Atrophy Carrier Screening (MLPA)
Price (AED)	1500
Turnaround Time	7–10 days
Sample Type / Matrix	Peripheral whole blood (EDTA or ACD tube)
Methodology Used	Multiplex Ligation-dependent Probe Amplification (MLPA)
ICD-10-CM Code	Z13.89 (Encounter for screening for other genetic and chromosomal anomalies)
LOINC Code	81314-9 (Spinal muscular atrophy carrier screening)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE